{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:43:41Z","timestamp":1762296221238,"version":"build-2065373602"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-025-03378-4","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:11:34Z","timestamp":1762251094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of long-acting muscarinic antagonists for severe asthma: insights from clinicians in the SHARP network"],"prefix":"10.1186","volume":"26","author":[{"given":"Alessandro","family":"Marcon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aruna T.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Berret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolos","family":"Bossios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierpaolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celeste","family":"Porsbjerg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Principe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Schleich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Sergejeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob K.","family":"Sont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Caminati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"3378_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/17534666251332076","volume":"19","author":"E Ridolo","year":"2025","unstructured":"Ridolo E, Milanese M, Barone A, Nicoletta F, Ottoni M, Cosini FF, et al. Extrafine formulation of beclomethasone dipropionate\/formoterol fumarate\/glycopyrronium bromide delivered via pressurized metered-dose inhaler in the treatment of asthma: a review. Ther Adv Respir Dis. 2025;19:17534666251332076. https:\/\/doi.org\/10.1177\/17534666251332076.","journal-title":"Ther Adv Respir Dis"},{"key":"3378_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7473690","author":"E Hamelmann","year":"2018","unstructured":"Hamelmann E. Managing severe asthma: a role for the long-acting muscarinic antagonist Tiotropium. BioMed Res Int. 2018. https:\/\/doi.org\/10.1155\/2018\/7473690.","journal-title":"BioMed Res Int"},{"key":"3378_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011721.pub2","author":"KM Kew","year":"2016","unstructured":"Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2 -agonists and inhaled corticosteroids (LABA\/ICS) versus LABA\/ICS for adults with asthma. Cochrane Database Syst Reviews. 2016. https:\/\/doi.org\/10.1002\/14651858.CD011721.pub2.","journal-title":"Cochrane Database Syst Reviews"},{"key":"3378_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejim.2021.01.027","volume":"85","author":"A Papi","year":"2021","unstructured":"Papi A, Fabbri LM, Kerstjens HAM, Rogliani P, Watz H, Singh D. Inhaled long-acting muscarinic antagonists in asthma \u2013 a narrative review. Eur J Intern Med. 2021;85:14\u201322. https:\/\/doi.org\/10.1016\/j.ejim.2021.01.027.","journal-title":"Eur J Intern Med"},{"key":"3378_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","volume":"205","author":"HK Reddel","year":"2022","unstructured":"Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Am J Respir Crit Care Med. 2022;205:17\u201335. https:\/\/doi.org\/10.1164\/rccm.202109-2205PP.","journal-title":"Am J Respir Crit Care Med"},{"key":"3378_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2147\/JAA.S274245","volume":"13","author":"F Puggioni","year":"2020","unstructured":"Puggioni F, Brussino L, Canonica GW, Blasi F, Paggiaro P, Caminati M, et al. Frequency of Tiotropium bromide use and clinical features of patients with severe asthma in a real-life setting: data from the severe asthma network in Italy (SANI) registry. J Asthma Allergy. 2020;13:599\u2013604. https:\/\/doi.org\/10.2147\/JAA.S274245.","journal-title":"J Asthma Allergy"},{"key":"3378_CR7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01671-2018","volume":"52","author":"R Djukanovic","year":"2018","unstructured":"Djukanovic R, Adcock IM, Anderson G, Bel EH, Canonica GW, Cao H, et al. The severe heterogeneous asthma research collaboration, patient-centred (SHARP) ERS clinical research collaboration: a new dawn in asthma research. Eur Respir J. 2018;52:1801671. https:\/\/doi.org\/10.1183\/13993003.01671-2018.","journal-title":"Eur Respir J"},{"key":"3378_CR8","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.1047","volume":"21","author":"G Heinze","year":"2002","unstructured":"Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med. 2002;21:2409\u201319. https:\/\/doi.org\/10.1002\/sim.1047.","journal-title":"Stat Med"},{"key":"3378_CR9","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1001\/jama.2020.21974","volume":"324","author":"MM Cloutier","year":"2020","unstructured":"Cloutier MM, Dixon AE, Krishnan JA, Lemanske RF, Pace W, Schatz M. Managing asthma in adolescents and adults: 2020 asthma guideline update from the National Asthma Education and Prevention Program. JAMA. 2020;324:2301\u201317. https:\/\/doi.org\/10.1001\/jama.2020.21974.","journal-title":"JAMA"},{"key":"3378_CR10","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0058-2020","author":"S Khurana","year":"2020","unstructured":"Khurana S, Bush A, Holguin F. Management of severe asthma: summary of the European respiratory society\/American thoracic society task force report. Breathe. 2020. https:\/\/doi.org\/10.1183\/20734735.0058-2020.","journal-title":"Breathe"},{"key":"3378_CR11","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0140-6736(19)32215-9","volume":"394","author":"JC Virchow","year":"2019","unstructured":"Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394:1737\u201349. https:\/\/doi.org\/10.1016\/S0140-6736(19)32215-9.","journal-title":"Lancet"},{"key":"3378_CR12","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00273-2022","volume":"8","author":"A-N Frix","year":"2022","unstructured":"Frix A-N, Heaney LG, Dahl\u00e9n B, Mihaltan F, Sergejeva S, Popovi\u0107-Grle S, et al. Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study. ERJ Open Res. 2022;8:00273\u20132022. https:\/\/doi.org\/10.1183\/23120541.00273-2022.","journal-title":"ERJ Open Res"},{"key":"3378_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-024-02870-9","volume":"24","author":"P Juntunen","year":"2024","unstructured":"Juntunen P, Salmela P, Pakkasela J, Karjalainen J, Lehtim\u00e4ki L. Diagnoses and prescription patterns among users of medications for obstructive airway diseases in Finland. BMC Pulm Med. 2024;24:64. https:\/\/doi.org\/10.1186\/s12890-024-02870-9.","journal-title":"BMC Pulm Med"},{"key":"3378_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2147\/JAA.S216932","volume":"12","author":"CM Averell","year":"2019","unstructured":"Averell CM, Lalibert\u00e9 F, Duh MS, Wu JW, Germain G, Faison S. Characterizing real-world use of Tiotropium in asthma in the USA. J Asthma Allergy. 2019;12:309\u201321. https:\/\/doi.org\/10.2147\/JAA.S216932.","journal-title":"J Asthma Allergy"},{"key":"3378_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2147\/COPD.S153655","volume":"13","author":"JR Hurst","year":"2018","unstructured":"Hurst JR, Dilleen M, Morris K, Hills S, Emir B, Jones R. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:781\u201392. https:\/\/doi.org\/10.2147\/COPD.S153655.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3378_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.rmed.2019.05.022","volume":"154","author":"DL Vetrano","year":"2019","unstructured":"Vetrano DL, Zucchelli A, Bianchini E, Cricelli C, Piraino A, Zibellini M, et al. Triple inhaled therapy in COPD patients: determinants of prescription in primary care. Respir Med. 2019;154:12\u20137. https:\/\/doi.org\/10.1016\/j.rmed.2019.05.022.","journal-title":"Respir Med"},{"key":"3378_CR17","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jaci.2020.06.014","volume":"146","author":"M Cazzola","year":"2020","unstructured":"Cazzola M, Rogliani P, Matera MG. The latest on the role of LAMAs in asthma. J Allergy Clin Immunol. 2020;146:1288\u201391. https:\/\/doi.org\/10.1016\/j.jaci.2020.06.014.","journal-title":"J Allergy Clin Immunol"},{"key":"3378_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s40413-017-0144-5","volume":"10","author":"MS Magnoni","year":"2017","unstructured":"Magnoni MS, Latorre M, Bettoncelli G, Sanchez-Herrero MG, Lopez A, Calvo E, et al. Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain. World Allergy Organ J. 2017;10:13. https:\/\/doi.org\/10.1186\/s40413-017-0144-5.","journal-title":"World Allergy Organ J"},{"key":"3378_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-021-00988-8","volume":"47","author":"G Cerimoniale","year":"2021","unstructured":"Cerimoniale G, Becherucci P, Verga MC, Di Mauro G, Indinnimeo L, Villani A, et al. Inhaled corticosteroids use in childhood respiratory diseases: an Italian survey on pediatricians\u2019 prescription habits. Ital J Pediatr. 2021;47:34. https:\/\/doi.org\/10.1186\/s13052-021-00988-8.","journal-title":"Ital J Pediatr"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03378-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-025-03378-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03378-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:26:24Z","timestamp":1762295184000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-025-03378-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3378"],"URL":"https:\/\/doi.org\/10.1186\/s12931-025-03378-4","relation":{},"ISSN":["1465-993X"],"issn-type":[{"type":"electronic","value":"1465-993X"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involved the participation of clinicians who completed an anonymous questionnaire. Participants were not recruited individually but were reached via emails by national societies or SHARP National Leads, without access to their personal information. Participation was voluntary, and informed consent was explicitly obtained at the beginning of the questionnaire (Additional file 3).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A. Bansal reports receipt of statistical consultancy fees from ERS and SHARP funding partners (GSK, Chiesi, Teva, Sanofi, Novartis); E. Berret reports salary support by ERS and SHARP funding partners (GSK, Chiesi, Teva, Sanofi, Novartis); A. Bossios reports a grant from AstraZeneca, and honoraria and lecture fees from Chiesi, GSK, and AstraZeneca, paid to his institution outside the submitted work; he is head of ERS Assembly 5 (Airway diseases, asthma, COPD, and chronic cough); he is a member of the Steering Committee of the Swedish National Airway Register; C. Porsbjerg reports grants or contracts in the past 36 months and consulting fees by AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, and ALK. S. Principe reports salary support by SANOFI, GSK, and AstraZeneca paid to her institution outside the submitted work; she is a member of the Young Investigator Board of the Netherlands Respiratory Society; F. Schleich received grants from GSK, Chiesi, AstraZeneca, and Sanofi, and consultation fees from GSK, AstraZeneca, Novartis, Chiesi, Teva, Celltrion, and Sanofi; J.K. Sont reports grants or contracts from the Dutch RAPSODI severe asthma registry, SHARP severe asthma registries, and AstraZeneca; he received equipment, materials, or other services from Bosch, Vivatmo me and Albus Health, Albus Home RD. The rest of the authors report no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"306"}}